Chris Brinsmead, President of AstraZeneca in the UK, has been named as President Designate of the Association of the British Pharmaceutical Industry (ABPI).
Mr Brinsmead will take over from the current ABPI President, Nigel Brooksby of sanofi-aventis (UK), in April next year. He will serve for a two-year term.
“The UK Pharmaceutical Industry has an excellent record of working with the UK Government. This relationship has always been focused on ensuring that patients get the best treatment and that this represents good value for the NHS,” said Mr Brinsmead. “At a time of considerable change for the NHS and also for industry we must make sure that we strengthen this partnership.
“In taking over the reins from Nigel Brooksby, I will continue to seek to ensure that patients have access to the appropriate medicines, that industry works in a way which meets the needs of professionals in the NHS, and that we can continue to focus on finding cures for the many unsolved medical needs at a cost which healthcare systems can afford.
“I commit to work with all stakeholders to build on past successes so that future generations can have access to new innovative medicines which address unmet need. I will encourage openness, engagement and a willingness to work together in achieving these shared goals.”
Mr Brinsmead leads the AstraZeneca UK Marketing Company. AstraZeneca employs around 10,000 staff involved in research, development, manufacturing and marketing of pharmaceuticals. He graduated in with a degree in Engineering joining ICI in 1980. For the ABPI, Mr Brinsmead is a member of the Governance Board and has been a member of the ABPI Board of Management since 2002. He is married with two daughters.
Note To Editors:
An electronic photograph of Chris Brinsmead is available on request.